Up-regulation of cartilage oligomeric matrix protein at the onset of articular cartilage degeneration in a transgenic mouse model of osteoarthritis
Open Access
- 1 August 2000
- journal article
- basic science
- Published by Wiley in Arthritis & Rheumatism
- Vol. 43 (8) , 1742-1748
- https://doi.org/10.1002/1529-0131(200008)43:8<1742::aid-anr10>3.0.co;2-u
Abstract
Objective To investigate the suitability of cartilage oligomeric matrix protein (COMP) as a marker for articular cartilage degeneration in a transgenic mouse model of osteoarthritis (OA). Methods Northern blot analysis of total RNA extracted from the knee joints of transgenic Del1 mice, which harbor a short deletion in a type II collagen transgene, and of their nontransgenic littermates was used to monitor changes in COMP messenger RNA (mRNA) levels during cartilage degeneration. Immunohistochemistry was used to determine the distribution of COMP in articular cartilage, and serum levels of COMP were measured by immunoassay. Results Transient up-regulation of COMP mRNA was seen in articular cartilage of transgenic Del1 mice at the onset of OA lesions at the age of 3 months. Compared with nontransgenic controls, COMP immunostaining of articular cartilage in 3–9-month-old transgenic mice was increased, especially at the border of uncalcified and calcified cartilage. There was also a change from predominantly interterritorial to pericellular/territorial deposition of COMP. This difference persisted until the age of 15 months, when the nontransgenic controls also demonstrated articular cartilage degeneration and increased COMP immunostaining. Increased serum levels of COMP were seen in Del1 mice at the age of 4 months, correlating temporally with the onset of cartilage degeneration. Conclusion These findings suggest that up-regulation of COMP mRNA and redistribution of the protein are characteristic of the early stages of articular cartilage degeneration in the transgenic mouse model in which OA results from a dominant-negative mutation in the type II collagen gene. The data provide additional support for the notion that COMP is a useful marker for altered cartilage metabolism in developing OA.Keywords
This publication has 36 references indexed in Scilit:
- Osteoarthritis-like lesions in transgenic mice harboring a small deletion mutation in type II collagen geneOsteoarthritis and Cartilage, 2000
- Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblastsOsteoarthritis and Cartilage, 1998
- Multiple epiphyseal dysplasia, ribbing type: A novel point mutation in the COMP gene in a South African familyAmerican Journal of Medical Genetics, 1997
- Distribution and expression of cartilage oligomeric matrix protein and bone sialoprotein show marked changes during rat femoral head developmentMatrix Biology, 1995
- Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism.Journal of Clinical Investigation, 1995
- Cartilage metabolism in the injured and uninjured knee of the same patient.Annals of the Rheumatic Diseases, 1994
- Cartilage oligomeric matrix protein (COMP) is an abundant component of tendonFEBS Letters, 1994
- An inbred line of transgenic mice expressing an internally deleted gene for type II procollagen (COL2A1). Young mice have a variable phenotype of a chondrodysplasia and older mice have osteoarthritic changes in joints.Journal of Clinical Investigation, 1993
- Chondrodysplasia in transgenic mice harboring a 15-amino acid deletion in the triple helical domain of pro alpha 1(II) collagen chain.The Journal of cell biology, 1992
- The Biology of OsteoarthritisNew England Journal of Medicine, 1989